glp 1 semaglutide or tirzepatide & are transforming diabetes & obesity management. These GLP-1 receptor agonists offer benefits from glycemic control to weight loss and cardiovascular risk reduction, emphasizing their broad impact. Read more from The GLP-1 Solution: 175+ Strategies,

doi: 10.1111/dom.14831 109 MertensILVan GaalLF

The results showed that treatment with Tesofensine led to significant weight reduction compared to the placebo group

Unlike some competitors, it does not offer a money-back policy on medications, and refunds for unused months are only granted in limited cases

It would randomize enough participants to BPC-157 or placebo, stratify for hypertension and cardiovascular medications, and use standardized office readings plus 24-hour ambulatory monitoring

Llata E, Cuffe KM, Picchetti V, Braxton JR, Torrone EA

Regarding liraglutide 3 mg (Saxenda) : whilst it holds a UK marketing authorisation for weight management, NICE has not issued a positive technology appraisal for its use in obesity in adults within the NHS in England